DHA protects against experimental colitis in IL-10-deficient mice associated with the modulation of intestinal epithelial barrier function

British Journal of Nutrition

Volumn 114, Issue 2, 2015, Pages 181-188

  Zhao, Jie ^a   Shi, Peiliang ^b   Sun, Ye ^b   Sun, Jing ^a   Dong, Jian Ning ^a   Wang, Hong Gang ^a   Zuo, Lu Gen ^a   Gong, Jian Feng ^a   Li, Yi ^a   Gu, Li Li ^a   Li, Ning ^a   Li, Jie Shou ^a   Zhu, Wei Ming ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b NANJING UNIVERSITY   (China)

Author keywords

Crohn's disease; DHA; Epithelial cell apoptosis; IL 10 deficient mice; Intestinal barrier function

Indexed keywords

DOCOSAHEXAENOIC ACID; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; OCCLUDIN; PROTEIN ZO1; TUMOR NECROSIS FACTOR ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OCLN PROTEIN, MOUSE; TJP1 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; COLON MUCOSA; CONTROLLED STUDY; EXPERIMENTAL COLITIS; GENE EXPRESSION; INTESTINAL BARRIER FUNCTION; INTESTINE EPITHELIUM CELL; INTESTINE FUNCTION; INTESTINE MUCOSA PERMEABILITY; MOUSE; NONHUMAN; PROTEIN LOCALIZATION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; COLITIS; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; GENETICS; INFLAMMATORY BOWEL DISEASES; INTESTINE; INTESTINE MUCOSA; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY;

MUS;

ANIMALS; APOPTOSIS; COLITIS; DISEASE MODELS, ANIMAL; DOCOSAHEXAENOIC ACIDS; INFLAMMATORY BOWEL DISEASES; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-17; INTESTINAL MUCOSA; INTESTINES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NF-KAPPA B; OCCLUDIN; TUMOR NECROSIS FACTOR-ALPHA; ZONULA OCCLUDENS-1 PROTEIN;

EID: 84938555754     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114515001294     Document Type: Article

References (54)

1. Kaser A, Zeissig S, & Blumberg RS. (2010). Inflammatory bowel disease. Am J Clin Nutr 28, 573-621
2. Xavier RJ, & Podolsky DK. (2007). Unravelling the pathogenesis of inflammatory bowel disease. Nature 448, 427-434
3. Harhaj NS, & Antonetti DA. (2004). Regulation of tight junctions and loss of barrier function in pathophysiology. Int J Biochem Cell Biol 36, 1206-1237
4. Juric M, Xiao F, Amasheh S, et al. (2013). Increased epithelial permeability is the primary cause for bicarbonate loss in inflamed murine colon. Inflamm Bowel Dis 19, 904-911
5. Schulzke JD, Ploeger S, Amasheh M, et al. (2009). Epithelial tight junctions in intestinal inflammation. Ann N Y Acad Sci 1165, 294-300
6. Clayburgh DR, Shen L, & Turner JR. (2004). A porous defense: the leaky epithelial barrier in intestinal disease. Lab Invest 84, 282-291
7. Schumann M, Gunzel D, Buergel N, et al. (2012). Cell polarity-determining proteins Par-3 and PP-1 are involved in epithelial tight junction defects in coeliac disease. Gut 61, 220-228
8. Su L, Nalle SC, Shen L, et al. (2013). TNFR2 activates MLCK-dependent tight junction dysregulation to cause apoptosis-mediated barrier loss and experimental colitis. Gastroenterology 145, 407-415
9. Carter PR, Watts MN, Kosloski-Davidson M, et al. (2013). Iron status, anemia, and plasma erythropoietin levels in acute and chronic mouse models of colitis. Inflamm Bowel Dis 19, 1260-1265
10. Yin H, Li X, Zhang B, et al. (2013). Sirolimus ameliorates inflammatory responses by switching the regulatory T/T helper type 17 profile in murine colitis. Immunology 139, 494-502
11. Goettel JA, Scott AH, Olivares-Villagomez D, et al. (2011). KSR1 protects from interleukin-10 deficiency-induced colitis in mice by suppressing T-lymphocyte interferon-gamma production. Gastroenterology 140, 265-274
12. Ouyang W, Rutz S, Crellin NK, et al. (2011). Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol 29, 71-109
13. Wang H, Dong J, Zuo L, et al. (2014). Anti-mouse CD52 monoclonal antibody ameliorates iron-deficient anaemia in IL-10 knockout mice. Br J Nutr 111, 987-995
14. Kaser A, Zeissig S, & Blumberg RS. (2010). Inflammatory bowel disease. Annu Rev Immunol 28, 573-621
15. Borrelli O, Cordischi L, Cirulli M, et al. (2006). Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled openlabel trial. Clin Gastroenterol Hepatol 4, 744-753
16. Froslie KF, Jahnsen J, Moum BA, et al. (2007). Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 133, 412-422
17. Hashimoto T, Perlot T, Rehman A, et al. (2012). ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature 487, 477-481
18. Hokari R, Matsunaga H, & Miura S. (2013). Effect of dietary fat on intestinal inflammatory diseases. J Gastroenterol Hepatol 28, Suppl. 4, 33-36
19. Ananthakrishnan AN, Khalili H, Konijeti GG, et al. (2014). Long-term intake of dietary fat and risk of ulcerative colitis and Crohn's disease. Gut 63, 776-784
20. Hou JK, Abraham B, & El-Serag H. (2011). Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. Am J Gastroenterol 106, 563-573
21. Neuman MG, & Nanau RM. (2012). Inflammatory bowel disease: role of diet, microbiota, life style. Transl Res 160, 29-44
22. Lev-Tzion R, Griffiths AM, & Leder O, et al. (2014). Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease. The Cochrane Database of Systematic Review 2014, issue 2, CD006320
23. Marion-Letellier R, Savoye G, Beck PL, et al. (2013). Polyunsaturated fatty acids in inflammatory bowel diseases: a reappraisal of effects and therapeutic approaches. Inflamm Bowel Dis 19, 650-661
24. Pizato N, Bonatto S, Piconcelli M, et al. (2006). Fish oil alters T-lymphocyte proliferation and macrophage responses in Walker 256 tumor-bearing rats. Nutrition 22, 425-432
25. Draper E, Reynolds CM, Canavan M, et al. (2011). Omega-3 fatty acids attenuate dendritic cell function via NF-kB independent of PPAR-g. J Nutr Biochem 22, 784-790
26. Calder PC. (2006). n-3 Polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 83, 1505S-1519S
27. Weylandt KH, Chiu CY, Gomolka B, et al. (2012). Omega-3 fatty acids and their lipid mediators: towards an understanding of resolvin and protectin formation. Prostaglandins Other Lipid Mediat 97, 73-82
28. Beguin P, Errachid A, Larondelle Y, et al. (2013). Effect of polyunsaturated fatty acids on tight junctions in a model of the human intestinal epithelium under normal and inflammatory conditions. Food Funct 4, 923-931
29. Singh UP, Singh S, Taub DD, et al. (2003). Inhibition of IFN-ginducible protein-10 abrogates colitis in IL-102/2 mice. J Immunol 171, 1401-1406
30. Arrieta MC, Madsen K, Doyle J, et al. (2009). Reducing small intestinal permeability attenuates colitis in the IL10 genedeficient mouse. Gut 58, 41-48
31. Gu L, Li N, Gong J, et al. (2011). Berberine ameliorates intestinal epithelial tight-junction damage and down-regulates myosin light chain kinase pathways in a mouse model of endotoxinemia. J Infect Dis 203, 1602-1612
32. Clayburgh DR, Barrett TA, Tang Y, et al. (2005). Epithelial myosin light chain kinase-dependent barrier dysfunction mediates T cell activation-induced diarrhea in vivo. J Clin Invest 115, 2702-2715
33. Wang H, Zhang W, Zuo L, et al. (2014). Intestinal dysbacteriosis contributes to decreased intestinal mucosal barrier function and increased bacterial translocation. Lett Appl Microbiol 58, 384-392
34. Wang H, Dong J, Shi P, et al. (2015). Anti-mouse CD52 mAb ameliorates intestinal epithelial barrier function in IL-10 knockout mice with spontaneous chronic colitis. Immunology 144, 254-262
35. Stewart M, Day AS, & Otley A. (2011). Physician attitudes and practices of enteral nutrition as primary treatment of paediatric Crohn disease in North America. J Pediatr Gastroenterol Nutr 52, 38-42
36. Cabre E, Manosa M, & Gassull MA. (2012). Omega-3 fatty acids and inflammatory bowel diseases -a systematic review. Br J Nutr 107, Suppl. 2, S240-S252
37. Lee D, Albenberg L, Compher C, et al. (2015). Diet in the pathogenesis and treatment of inflammatory bowel diseases. Gastroenterology (Epublication ahead of print version
38. Tapia G, Valenzuela R, Espinosa A, et al. (2014). n-3 Longchain PUFA supplementation prevents high fat diet induced mouse liver steatosis and inflammation in relation to PPAR-a upregulation and NF-kB DNA binding abrogation. Molec Nutr Food Res 58, 1333-1341
39. Adkins Y, & Kelley DS. (2010). Mechanisms underlying the cardioprotective effects of omega-3 polyunsaturated fatty acids. J Nutr Biochem 21, 781-792
40. Berg DJ, Davidson N, Kuhn R, et al. (1996). Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4 TH1-like responses. J Clin Invest 98, 1010-1020
41. Mbodji K, Charpentier C, Guerin C, et al. (2013). Adjunct therapy of n-3 fatty acids to 5-ASA ameliorates inflammatory score and decreases NF-kB in rats with TNBS-induced colitis. J Nutr Biochem 24, 700-705
42. Campos FG, Waitzberg DL, Habr-Gama A, et al. (2002). Impact of parenteral n-3 fatty acids on experimental acute colitis. Br J Nutr 87, Suppl. 1, S83-S88
43. Abraham C, & Cho JH. (2009). Inflammatory bowel disease. N Engl J Med 361, 2066-2078
44. Hering NA, Fromm M, & Schulzke JD. (2012). Determinants of colonic barrier function in inflammatory bowel disease and potential therapeutics. J Physiol 590, 1035-1044
45. Watson AJ, Chu S, Sieck L, et al. (2005). Epithelial barrier function in vivo is sustained despite gaps in epithelial layers. Gastroenterology 129, 902-912
46. Vandenbroucke RE, Dejonckheere E, Van Hauwermeiren F, et al. (2013). Matrix metalloproteinase 13 modulates intestinal epithelial barrier integrity in inflammatory diseases by activating TNF. EMBO Mol Med 5, 932-948
47. Vivinus-Nebot M, Frin-Mathy G, Bzioueche H, et al. (2014). Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation. Gut 63, 744-752
48. Poritz LS, Harris LR, Kelly AA, et al. (2011). Increase in the tight junction protein claudin-1 in intestinal inflammation. Dig Dis Sci 56, 2802-2809
49. Jansson J, Willing B, Lucio M, et al. (2009). Metabolomics reveals metabolic biomarkers of Crohn's disease. PLoS One 4, e6386
50. Hekmatdoost A, Feizabadi MM, Djazayery A, et al. (2008). The effect of dietary oils on cecal microflora in experimental colitis in mice. Indian J Gastroenterol 27, 186-189
51. Knoch B, Nones K, Barnett MP, et al. (2010). Diversity of caecal bacteria is altered in interleukin-10 gene-deficient mice before and after colitis onset and when fed polyunsaturated fatty acids. Microbiology 156, 3306-3316
52. Wang X, Pan L, Lu J, et al. (2012). n-3 PUFAs attenuate ischemia/reperfusion induced intestinal barrier injury by activating I-FABP-PPARg pathway. Clin Nutr 31, 951-957
53. Bansal T, Alaniz RC, Wood TK, et al. (2010). The bacterial signal indole increases epithelial-cell tight-junction resistance and attenuates indicators of inflammation. Proc Natl Acad Sci USA 107, 228-233
54. Zeissig S, Burgel N, Gunzel D, et al. (2007). Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease. Gut 56, 61-72